EUVIMEDEUVIMED entdecken
Crossref

On-Site Therapeutic Drug Monitoring for Program Death-1 Antibody Using a Quantum Dot Nanobeads-Based Lateral Flow Immunoassay

Wenwen Xia, Ying Wu, Xiangyi Liao, Lili Cui, Huanxing Han, Juanjuan Hou, Zhipeng Wang, Pengfei Zhang iD, Shouhong Gao

Analytical Chemistry · 2025

DOI: 10.1021/acs.analchem.5c02078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Wenwen Xia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China. Hauptthemen laut MEDLINE: Quantum Dots, Drug Monitoring, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, International Science and Technology Cooperation Programme, Science and Technology Innovation Plan Of Shanghai Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic drug monitoring of program death-1 (PD-1) inhibitor Serplulimab in cancer patients is of clinical importance in predicting treatment efficacy and assessing adverse reactions. However, the traditional liquid chromatography tandem mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA) for antibody drug monitoring are time-consuming and laborious. Herein, a quantum dot nanobeads-based lateral flow immunoassay (LFIA) is developed for rapid and accurate monitoring of the PD-1 antibody drug in 15 min. Both competitive and indirect immunoassays were investigated for PD-1 antibody drug monitoring, and the competitive assay demonstrated better sensitivity and precision. The optimized competitive LFIA had a detection of limit of 5.1 μg/mL; a linear range of 10-100 μg/mL; recovery rates of 99.2%-113.9% at the spiked concentration of 25, 50 and 100 μg/mL; and coefficients of variations (CVs, n = 10) less than 14.5% at 50 μg/mL. The assay has a negligible nonspecific reaction with the interferents of other monoclonal antibody drugs, autoantibodies, hyper lipids, hemolysis, jaundice, and whole blood samples. Method comparison with ELISA in 30 human plasma samples has a good correlation factor of r = 0.87. All in all, the developed quantum dot nanobead-based LFIA system for PD-1 antibody drug monitoring is a versatile tool for rapidly personalized drug therapy at the point of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quantum DotsDrug MonitoringProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedHumansImmunoassayLimit of Detection

Substanzen

Programmed Cell Death 1 ReceptorPDCD1 protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pharmacy, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.
  • College of Traditional Chinese Medicine, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, China.
  • Phase I Clinical Trial Unit, The First Affiliated Hospital With Nanjing Medical University, Nanjing 210029, China.
  • Department of Oncology, Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.
  • Zhengzhou Foreign Language School New Fengyang Campus, Zhengzhou 450001, China.
  • Department of Central Laboratory, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China.

ORCID-Profile: Pengfei Zhang

Förderung

  • National Natural Science Foundation of China
  • International Science and Technology Cooperation Programme
  • Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
  • Clinical Research Incubation Program of Shanghai Skin Disease Hospital

Zitieren

APA

Xia, W., Wu, Y., Liao, X., Cui, L., Han, H., Hou, J., Wang, Z., Zhang, P., & Gao, S. (2025). On-Site Therapeutic Drug Monitoring for Program Death-1 Antibody Using a Quantum Dot Nanobeads-Based Lateral Flow Immunoassay. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.5c02078

Vancouver

Xia W, Wu Y, Liao X, Cui L, Han H, Hou J, et al. On-Site Therapeutic Drug Monitoring for Program Death-1 Antibody Using a Quantum Dot Nanobeads-Based Lateral Flow Immunoassay. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.5c02078

BibTeX
@article{Xia2025,
  author = {Xia, Wenwen and Wu, Ying and Liao, Xiangyi and Cui, Lili and Han, Huanxing and Hou, Juanjuan and Wang, Zhipeng and Zhang, Pengfei and Gao, Shouhong},
  title = {On-Site Therapeutic Drug Monitoring for Program Death-1 Antibody Using a Quantum Dot Nanobeads-Based Lateral Flow Immunoassay},
  journal = {Analytical Chemistry},
  year = {2025},
  doi = {10.1021/acs.analchem.5c02078}
}
Kostenlos starten →